NeonMind Biosciences Inc: NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity
NeonMind Biosciences Inc: NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity NeonMind Biosciences Inc. (CSE: NEON) (" NeonMind"), a psychedelic drug development company, is pleased to announce that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia whe...
Source: finanznachrichten.de